Clinical profile and outcome of posterior reversible encephalopathy syndrome in hemodialysis patients

• Published in: Indian journal of nephrology 2018-07, Vol.28 (4), p.283-286
• Main Authors: Chandragiri, S, Surendra, M, Raju, S, Sridhar, N, Ramesh, B, Raju, N
• Format: Article
• Language: English
• Subjects: Anticonvulsants; Biopsy; Blood pressure; Diagnosis; Dosage and administration; Edema; Encephalopathy; Headaches; Health aspects; Hemodialysis; Hemodialysis patients; Hypertension; Infections; Kidney diseases; Kidney transplantation; Mortality; Original; Patient outcomes; Patients; Population; Risk factors; Safety and security measures; Sepsis; Tuberculosis
• ISSN: 0971-4065; 1998-3662
• DOI: 10.4103/ijn.IJN_237_17

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic entity characterized by headache, altered level of consciousness, seizures, visual disturbances, and reversible vasogenic subcortical edema. Hypertension and renal failure are well known principal risk factors for the development of PRES. However, risk factors and outcome of PRES has not been studied in patients on maintenance hemodialysis (MHD). The objective of this study is to characterize the factors predisposing to the development of PRES in patients on MHD. We performed a retrospective analysis in patients of MHD who were diagnosed with PRES between August 1, 2013, and July 31, 2015. Those with a history of cerebrovascular accidents/stroke, and epilepsy were excluded. We analyzed the clinical details, course, and laboratory data. One year follow-up data were noted in recurrence of PRES and mortality. A total of 18 patients were included for the final analysis. Of these, 13 (72%) patients were males. Majority of these patients were young and mean age was 21.1 years (6-50 years). Most of the PRES episodes developed shortly after initiation of MHD with mean duration of 2 months after initiation of MHD (1 month-3 years). All 18 patients had resistant hypertension. Eight (45%) patients had infection at the time of PRES episodes. Four patients had catheter-related bloodstream infection, 1 had pneumonia and 3 patients were recently diagnosed with pulmonary tuberculosis. Four (22%) patients developed recurrence of PRES and all these episodes developed within 2 months of index event. Seven (39%) patients underwent renal transplantation, and all received triple immune suppression and had uncontrolled hypertension in the perioperative period. However, none of these patients developed PRES after transplantation. All these patients had been maintaining stable graft function in the follow-up. All episodes of PRES were of generalized tonic-clonic seizure type and 6 of them presented as status epilepticus. None of them had any neurological sequel and no mortality at the end of 1 year. PRES is not uncommon in patients on MHD. Uncontrolled hypertension and infection are common predisposing factors. Renal transplantation is safe and not adversely affected by prior episodes of PRES in MHD.